Tenofovir Disoproxil Fumarate

Tenofovir Disoproxil Fumarate (TDF) created by Gilead Sciences for the treatment of HIV has been linked to bone and kidney damages. Since 2001, TDF has been compounded into the following medications:

  • Truvada

  • Viread

  • Atripla

  • Stribild

  • Complera














TDF works by blocking the effectiveness of reverse transcriptase, an enzyme required for the viruses to make copies. Since TDF is no readily absorbed by the body, higher doses are required for it to be effective. Higher doses have been linked to:

  • Kidney Damage

    • Kidney Disease

    • Kidney Failure

    • Renal Impairment

    • Acute Kidney Injury

    • Fanconi Syndrome

    • Tubular Dysfunction

  • Bone Damage

    • Osteoporosis

    • Osteopenia

    • Bone Fractures

    • Dental Damage

    • Bone Density Loss


According to an article in the Los Angeles Times, scientists working for Gilead were aware early on that their drug could cause serious damage to the kidneys and bones. Even as Viread came onto the market in 2001, Gilead’s research and development team was working on a slightly different version of the drug called “tenofovir alafenamide fumarate (“TAF”), which showed in animal studies to have a greater effect against HIV than TDF, with the potential to be far less toxic.


If you or a loved one took a TDF drug and suffered a bone or kidney injury, contact the firm today for a complimentary consultation.